Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma

Li, Hong; Huang, Lan; Liu, Linbo; Wang, Ximei; Zhang, Zhen; Yue, Dongli; He, Wei; Fu, Kun; Guo, Xingyi; Huang, Jianmin; Zhao, Xuan; Zhu, Yu; Wang, Liping; Wu, Dong; Yan, Yan; Xu, Li; Gao, Ming; Yang, Shuman; Zhang, Yi

doi:10.1007/s00262-016-1939-x

Cited by 12 publications

(14 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed that CIK cell treatment prolonged the OS of patients with TNBC who were in stages N1, N2, and N3, although this result was not observed for patients with stage N0, I, IIA, IIB, or III disease [ 25 26 ]. In our study, we found that the patients in the early stages received the greatest benefit from CIK cell immunotherapy, and this result is consistent with some previous studies [ 27 28 ]. This may indicate that the immune function of patients with advancedstage TNBC is suppressed and that a high tumor burden influences the therapeutic effects of CIK cells [ 29 ].…”

Section: Discussionsupporting

confidence: 93%

Efficiency of Cytokine-Induced Killer Cells in Combination with Chemotherapy for Triple-Negative Breast Cancer

Wang

Wei

et al. 2018

J Breast Cancer

View full text Add to dashboard Cite

PurposeThe treatment of triple-negative breast cancer (TNBC) remains challenging, due to the absence of estrogen, progesterone, and human epidermal growth factor receptors. This study was designed to evaluate the efficiency and safety of cytokine-induced killer (CIK) cell immunotherapy, following regular chemotherapy, for patients with TNBC.MethodsA total of 340 patients with postmastectomy TNBC, from January 1, 2010 to June 30, 2014, were included in this retrospective study. Seventy-seven patients received CIK cell immunotherapy, following regular chemotherapy (arm 1), and 263 patients received regular chemotherapy alone (arm 2). The primary aim was overall survival (OS) and disease-free survival (DFS), and the treatment responses and adverse events were also evaluated.ResultsThe 5-year DFS and OS rates in arm 1 were 77.9% and 94.3%, compared with 69.8% and 85.6% in arm 2, respectively (p=0.159 and p=0.035, respectively). This clearly shows that there was no statistical difference in the 5-year DFS between the two groups. Multivariate analyses of arm 1 indicated that a Karnofsky performance score (KPS) ≥90 and stage I/IIA disease were significantly associated with a prolonged DFS period (hazard ratio [HR], 0.25; 95% confidence interval [CI], 0.09–0.74; p=0.012; and HR 0.21; 95% CI, 0.06–0.82; p=0.024, respectively), but a KPS ≥90 and stage I/IIA disease were not independent prognostic factors for OS. Toxicity was mild in patients who received the CIK therapy.ConclusionThe data suggested that CIK cell immunotherapy improved the efficiency of regular chemotherapy in patients with TNBC, and the side effects of CIK cell immunotherapy were mild.

show abstract

Section: Discussionsupporting

confidence: 93%

Efficiency of Cytokine-Induced Killer Cells in Combination with Chemotherapy for Triple-Negative Breast Cancer

Wang

Wei

et al. 2018

J Breast Cancer

View full text Add to dashboard Cite

show abstract

“…We found that CIK treatment combined with chemotherapy could effectively reduce the recurrence and metastasis in TNBC patients, thereby prolonging overall survival, and it had a stronger effect on patients at relatively early-stage of the disease. The conclusion that the patients in the early stages are the ones most benefited from CIK treatment was in line with some of the results from available studies on the treatment of other early-stage tumors by CIK immune cells 26, 27 . Several mechanisms could further contribute to the observed phenomenon.…”

Section: Discussionsupporting

confidence: 81%

Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients

Zhang

Wang

Yang

et al. 2019

Cancer Biology & Medicine

View full text Add to dashboard Cite

Objective To examine the efficacy and safety of a sequential combination of chemotherapy and autologous cytokine-induced killer (CIK) cell treatment in triple-negative breast cancer (TNBC) patients. Methods A total of 294 post-surgery TNBC patients participated in the research from January 1, 2009 to January 1, 2015. After adjuvant chemotherapy, autologous CIK cells were introduced in 147 cases (CIK group), while adjuvant chemotherapy alone was used to treat the remaining 147 cases (control group). The major endpoints of the investigation were the disease-free survival (DFS) and overall survival (OS). Additionally, the side effects of the treatment were evaluated. Results In the CIK group, the DFS and OS intervals of the patients were significantly longer than those of the control group (DFS: P = 0.047; OS: P = 0.007). The multivariate analysis demonstrated that the TNM (tumor-node-metastasis) stage and adjuvant CIK treatment were independent prognostic factors for both DFS [hazard ratio (HR) = 0.520, 95% confidence interval (CI):0.271-0.998, P = 0.049; HR = 1.449, 95% CI:1.118-1.877, P = 0.005, respectively] and OS (HR=0.414, 95% CI:0.190-0.903, P = 0.027; HR = 1.581, 95% CI:1.204-2.077, P = 0.001, respectively) in patients with TNBC. Additionally, longer DFS and OS intervals were associated with increased number of CIK treatment cycles (DFS: P = 0.020; OS: P = 0.040). The majority of the patients who benefitted from CIK cell therapy were relatively early-stage TNBC patients. Conclusion Chemotherapy in combination with adjuvant CIK could be used to lower the relapse and metastasis rate, thus effectively extending the survival time of TNBC patients, especially those at early stages.

show abstract

“…The hypothesis of the protein serum effect on cultured CIK cells was followed by Guo et al [30], Meng et al [21], and Li et al [37]. On the contrary, Niam et al [31] used a complete nutrient medium of RPMI-1640 and 10% fetal calf serum, claiming that this was the optimal medium for CIK cell expansion, better than other serum-free MNCs culture media, despite that, the CD3 + CD56 + effective subset reported comprised a median of 26.6%.…”

Section: Discussionmentioning

confidence: 99%

“…Guo et al [30], who cultured CIK cells from healthy volunteers' blood donors for 14 days, reported CD3 + CD56 + proportion on day 14 as 25.31 ± 7.42%. Li et al [37], who cultured CIK cells from patients with early-stage melanoma blood for 14 days, reported CD3 + CD56 + proportion on day 14 as 21.8 ± 8%. On the other hand, these results did not go in line with Bonanno et al [46], who cultured PBMCs with different concentrations of anti-CD3 antibody (50,250, and 250 ng/mL) reported that the proportion of CD3 + CD56 + subsets on day 21 were 69.6%, 47.9%, and 29.3%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Cytokine-Induced Killer Cells as an Adoptive Cellular Immunotherapy Strategy for Hepatocellular Carcinoma

El-Ashmawy¹

2019

BMB

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is the most common histologic type of primary liver cancer. HCC is the second highest mortality rate out of all major malignant carcinomas worldwide. Objectives: The aims of this study were to establish a rapid and easily handled culture method for sufficient expansion of viable and cytotoxic cytokine-induced killer (CIK) cells against HCC. Also, this study aimed to examine the morphologic, phenotypic, and functional characteristics of CIK cells. Method: Peripheral blood mononuclear cells (PBMCs) were cultured in a preliminary static culture to remove adherent cells. The suspended cells were cultured for 14 days with interferon-γ, human monoclonal anti-CD3 antibody and interleukin-2. Aliquots of induced PBMCs were harvested weekly to assess informative morphologic and phenotypic features of CIK cells. Mature CIK cells were subjected to functional assays that included the production of TNFα and the cytotoxic effect on HCC cell line, HepG2. Findings: CIK cells could be successfully expanded from all samples with a significant increase in T cells, natural killer cells, and natural killer T cells. TNFα concentration in the culture supernatant was significantly increased. The cytotoxic effect of CIK cells on HepG2 cells was nearly 60% at 40:1, effector: target ratio. Regression analysis was used to predict the CIK: HepG2 ratio required to achieve complete cytotoxicity. Conclusion: This study provides a detailed and simple strategy for culturing effective CIK cells. Mature CIK cells showed a high functional capacity against HCC; which will support the further ongoing practice of immunotherapy integration into different current cancer treatment protocols.

show abstract

Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma

Cited by 12 publications

References 37 publications

Efficiency of Cytokine-Induced Killer Cells in Combination with Chemotherapy for Triple-Negative Breast Cancer

Efficiency of Cytokine-Induced Killer Cells in Combination with Chemotherapy for Triple-Negative Breast Cancer

Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients

Cytokine-Induced Killer Cells as an Adoptive Cellular Immunotherapy Strategy for Hepatocellular Carcinoma

Contact Info

Product

Resources

About